Lakewood-Amedex Biotherapeutics Inc. Files S-1: RSU & Capital Gains Tax Exposure Calculator (Sep 19, 2026)

What Changed

Lakewood-Amedex Biotherapeutics filed its S-1 registration statement with the SEC on September 18, 2026. The 11 MB filing signals an upcoming IPO in the biotech sector. No pricing range or share count has been disclosed yet.

The Numbers That Matter

Metric	Pre-IPO Private Round (Estimated)	IPO Filing Range (TBD)	Typical Biotech IPO Discount	First-Day Pop (Historical Avg)
Valuation	Data not public	Pending pricing amendment	15% to 25% below last private round	18% to 22% for biotech S-1s since 2024
Lock-up period	Not applicable	180 days standard	Not applicable	Not applicable
Employee RSU liquidity	Zero	Begins at lock-up expiration	Not applicable	Not applicable
Institutional allocation	Not applicable	70% to 85% of float	Not applicable	Not applicable

The S-1 filing itself does not provide a valuation or price range. Those figures typically appear in amended S-1 filings 2 to 4 weeks before the roadshow begins. For employees holding pre-IPO equity, the full path to liquidity involves two phases: approximately 90 to 120 days from S-1 filing to IPO pricing, then 180 days of lock-up after the IPO date.

What This Means for Your Portfolio

If you hold Lakewood-Amedex equity as an employee or early investor, your position remains illiquid for at least 270 days from the S-1 filing date, assuming standard timelines (90 to 120 days to IPO pricing plus 180 days lock-up). On a $500K pre-IPO equity position valued at the last private round, a 20% IPO discount would reset your paper value to $400K before any first-day trading movement. After the lock-up expires, your net proceeds depend on whether the stock trades above or below the IPO price at that point.

Scenario Analysis

Pre-IPO Equity Position	IPO Discount (20%)	First-Day Pop (20%)	Value at Lock-Up Expiration (Flat)	Net Proceeds After Tax (37% Fed + State)
$500K	$400K	$480K	$480K	$302K
$1M	$800K	$960K	$960K	$605K
$2M	$1.6M	$1.92M	$1.92M	$1.21M

This table assumes the stock trades flat from first-day close to lock-up expiration. Biotech IPOs filed in 2024 and 2025 showed a median decline of 12% from first-day close to day 180. If Lakewood-Amedex follows that pattern, a $1M pre-IPO position would be worth $845K at lock-up expiration, yielding $532K after tax.

Why This Plays Out This Way

S-1 filings trigger a structured timeline. The company files the initial S-1 without pricing. The SEC reviews and issues comments within 30 days. The company files amendments addressing those comments and adds a price range. The roadshow begins 1 to 2 weeks after the pricing amendment. The IPO prices and begins trading within 1 to 3 days of roadshow completion. Employee lock-ups begin at the IPO date, not the S-1 filing date.

For Lakewood-Amedex employees, the lock-up clock does not start until shares begin trading. If the IPO prices in December 2026, lock-up expiration falls in June 2027. During that period, your equity is marked to market daily but remains unsellable. Margin loans against pre-IPO equity are not available until after the lock-up expires, and even then, most prime brokers will not lend against biotech positions under $1B market cap.

The IPO discount exists because institutional buyers demand a lower entry price than the last private round to compensate for near-term dilution and market risk. The first-day pop reflects retail demand that was excluded from the institutional allocation. Neither figure is guaranteed. Historical data from biotech S-1 filings shows that some deals price below the initial range and others are withdrawn entirely.

What To Consider With This Position

If you hold Lakewood-Amedex equity, consider modeling three scenarios: IPO prices at a 20% discount and trades flat, IPO prices at a 20% discount and declines 15% by lock-up expiration, and IPO prices at a 10% discount and rises 10% by lock-up expiration. Your tax liability crystallizes at sale, not at IPO. On a $1M position, the difference between the high and low scenario is $250K in net proceeds after tax.

Do not assume liquidity before June 2027 if the IPO prices in December 2026. Lock-ups are contractual and enforceable. Early exercise provisions in your equity grant documents do not override the IPO lock-up. If you need liquidity before mid-2027, this position will not provide it.

This article is for informational purposes only and should not be construed as financial advice. Consult a qualified tax professional or financial advisor before making decisions regarding pre-IPO equity positions.

The Scenario You Have Not Modelled

If Lakewood-Amedex withdraws the S-1 or postpones the IPO indefinitely, your equity remains illiquid with no clear path to a liquidity event. IPO withdrawals occur periodically in biotech markets when conditions shift. A withdrawal does not reset your equity to zero, but it does remove the near-term valuation benchmark the S-1 process provides. If you are counting on this position to fund a purchase, debt payoff, or portfolio rebalancing in 2027, you are currently holding execution risk that is not priced into your plan.

Frequently Asked Questions

Q: When does the lock-up period start? A: The lock-up period begins on the IPO pricing date, not the S-1 filing date, and typically runs 180 days.

Q: Can I sell shares on the first day of trading? A: No, employees and early investors are subject to the lock-up and cannot sell until it expires, usually 6 months after the IPO.

Q: What happens to my equity if the IPO is withdrawn? A: Your equity remains illiquid and valued at the last private round price until another liquidity event occurs or the company files a new S-1.

Q: How is the IPO price discount calculated? A: The discount is the percentage difference between the IPO price and the last private round valuation, typically 15% to 25% for biotech offerings.

Run the Numbers

Use CalcMoney's Calculate Your After-Tax RSU Proceeds to model your exact position value under different IPO pricing and post-lock-up trading scenarios.

Tags: #IPO #Biotech #EquityCompensation #TaxPlanning #Liquidity

Run the Numbers: Capital Gains Tax Terminal on CalcMoney — see your exact figures under current market conditions.

Data sourced from SEC EDGAR S-1 Filings (IPO). Rates and thresholds are for informational purposes only. Consult a licensed financial advisor before making mortgage, investment, or tax decisions.

Featured Partner

FIDELITY